Immortalisation and transformation revisited

Current Opinion in Genetics and Development

Volumn 12, Issue 1, 2002, Pages 98-104

  Drayton, Sarah ^a   Peters, Gordon ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARF PROTEIN; COMPLEMENTARY DNA; PROTEIN; PROTEIN INK4A; TELOMERASE; UNCLASSIFIED DRUG;

CELL IMMORTALIZATION; CELL TRANSFORMATION; CLONE; GENETIC CODE; HUMAN; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; SENESCENCE; TELOMERE;

EID: 0036467483     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-437X(01)00271-4     Document Type: Review

References (65)

1. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
2. Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture
3. Telomere loss: Mitotic clock or genetic time bomb?
4. Telomere dynamics in cancer progression and prevention: Fundamental differences in human and mouse telomere biology
5. Expression of mouse telomerase reverse transcriptase during development, differentiation and proliferation
6. Expression of mouse telomerase catalytic subunit in embryos and adult tissues
7. Extension of life-span by introduction of telomerase into normal human cells
8. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative lifespan
9. Creation of human tumour cells with defined genetic elements
10. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells
11. Absence of cancer-associated changes in human fibroblasts immortalized with telomerase
12. Longevity, stress response and cancer in aging telomerase-deficient mice
13. A critical role for telomeres in suppressing and facilitating carcinogenesis
14. Fibroblast immortality is a prerequisite for transformation by EJ c-Ha-ras oncogene
15. INK4a
16. Expression of catalytically active telomerase does not prevent premature senescence caused by overexpression of oncogenic Ha-Ras in normal human fibroblasts
17. Evidence for a telomere-independent 'clock' limiting RAS oncogene-driven proliferation of human thyroid epithelial cells
18. Cellular senescence: Mitotic clock or culture shock?
19. Extended culture of mouse embryo cells without senescence: Inhibition by serum
20. Putative telomere-independent mechanisms of replicative aging reflect inadequate growth conditions
21. Lack of replicative senescence in normal rodent glia
22. Lack of replicative senescence in cultured rat oligodendrocyte precursor cells
23. Defining the molecular mechanisms of human cell immortalization
24. INK4a/CDKN2A tumor suppressor and its relatives
25. The INK4a/ARF network in tumour suppression
26. Role of the INK4a locus in tumor suppression and cell mortality
27. ARF
28. Ink4a confers susceptibility to metastatic melanoma in mice
29. Arf predisposes mice to tumorigenesis
30. INK4b in undifferentiated mouse skin tumors
31. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis
32. Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis
33. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF
34. ARF) and is amplified in a subset of human breast cancers
35. Tumor spectrum in ARF-deficient mice
36. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53
37. Arf induces p53-dependent apoptosis during Abelson virus-mediated pre-B cell transformation
38. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization
39. ARF links the tumour suppressor p53 to Ras
40. ARF tumor suppressor
41. Inhibition of v-Abl transformation by p53 and p19ARF
42. Kip1 without activating cyclin D-dependent kinases
43. Oncogenic ras activates the ARF-p53 pathway to suppress epthelial cell transformation
44. INK4a in mouse fibroblasts as a function of replicative senescence and not of retinoblastoma gene status
45. Expression of INK4 inhibitors of cyclin D-dependent kinases during mouse brain development
46. Ink4a loss on senescence of murine bone marrow-derived preB cells and macrophages
47. Premature senescence involving p53 and p16 is activated in response to consitutive MEK/MAPK mitogenic signaling
48. Senescence of human fibroblasts induced by oncogenic Raf
49. INK4a expression during cellular senescence
50. PML is induced by oncogenic ras and promotes premature senescence
51. ARF in replicative and induced senescence of human fibroblasts
52. INK4A upon immortalization
53. Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation
54. Inactivation of p16 in human mammary epithelial cells by CpG island methylation
55. INK4 expression by methylation is associated with lifespan extension of human mammary epithelial cells
56. p16/pRb pathway alterations are required for bypassing senescence in human prostate epithelial cells
57. INK4a inactivation and telomerase activity are required to immortalize human epithelial cells
58. INK4a-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics
59. Genetic and epigenetic changes in human epithelial cells immortalized by telomerase
60. Normal human mammary epithelial cells spontaneously escape senescence and acquire genomic changes
61. Control of replicative life span in human cells: Barriers to clonal expansion intermediate between M1 senescence and M2 crisis
62. INK4 expression
63. CIP1 in spontaneously immortalized human fibroblasts
64. CIP1/WAF1 gene in normal diploid human fibroblasts
65. 2 arrest after DNA damage